Video Experimental Relacionado
Updated: Aug 9, 2026
08:42
Using Multi-fluorinated Bile Acids and In Vivo Magnetic Resonance Imaging to Measure Bile Acid Transport
Published on: November 27, 2016
Inhibidores de la prostaglandina sintetasa en el síndrome de Bartter. Efecto sobre la excreción inmunorreactiva de la
JAMA
|January 9, 1978
Resumen
Los antiinflamatorios no esteroideos (AINE) como la indometacina reducen efectivamente la excreción de prostaglandina E (PGE) en el Bartter.
Área de la Ciencia:
- Nefrología Nefrología.
- Endocrinología Endocrinología.
- Farmacología Farmacología.
Sus antecedentes:
- El síndrome de Bartter se caracteriza por un aumento de la excreción urinaria de prostaglandina E (iPGE).
- Las prostaglandinas juegan un papel en la patogénesis del síndrome de Bartter.
Objetivo del estudio:
- Para comparar los efectos de la indometacina, la aspirina y el ibuprofeno en el iPGE urinario y las manifestaciones clínicas en el síndrome de Bartter.
Principales métodos:
- Se midieron los niveles de iPGE en orina.
- Los efectos de la indometacina, la aspirina y el ibuprofeno en el equilibrio electrolítico, la actividad de la renina y el aclaramiento de la creatinina se evaluaron en cuatro pacientes.
Principales resultados:
- Cinco de los siete pacientes mostraron un aumento de iPGE urinario.
- La indometacina demostró una supresión superior de la iPGE urinaria en comparación con la aspirina o el ibuprofeno.
- La indometacina condujo a una mayor retención de sodio y potasio, aumento del potasio sérico, disminución de la actividad de la renina plasmática y reducción del aclaramiento de la creatinina.
Conclusiones:
- Existe una fuerte correlación entre la reducción de la excreción urinaria de iPGE y la mejora clínica en el síndrome de Bartter.
- Los inhibidores de la prostaglandina sintetasa son efectivos en el tratamiento del síndrome de Bartter, independientemente de su estructura química.
Videos de Conceptos Relacionados
01:15Drug Elimination by Renal Route: Tubular Secretion
Once the process of glomerular filtration is completed, blood carrying unfiltered drug molecules traverses through efferent arterioles and makes its way into the peritubular capillaries in the proximal tubule. A variety of carriers play a pivotal role in actively secreting drugs from these peritubular capillaries into the tubular fluid. The organic anion transporter transfers acidic drugs, against an electrochemical gradient, from the peritubular capillaries into the renal tubule cells and...
01:28Antihypertensive Drugs: Potassium-Sparing Diuretics
Liddle syndrome is a genetically inherited form of hypertension characterized by the overactivity of epithelial sodium channels in the nephron, the functional unit of the kidney. This heightened activity leads to increased sodium reabsorption and excessive excretion of potassium. To counteract this, potassium-sparing diuretics such as amiloride are used. They function by blocking these sodium channels, thereby reducing the influx of sodium into the epithelial cells and minimizing the loss of...
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
01:20Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents
The gastric mucosa produces prostaglandins E2 (PGE2) and prostacyclin (PGI2), crucial in maintaining gastric health. They exert cytoprotective effects, including increasing bicarbonate secretion, releasing protective mucin, reducing gastric acid output, and preventing harmful vasoconstriction. These effects are mediated through various receptors, such as EP1, EP2, EP3, and EP4.
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
01:29Drugs for Treatment of Ulcerative Colitis in IBD
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide generation.
01:28Renal Drug Excretion: Tubular Secretion
Active tubular secretion is a robust, energy-demanding process that utilizes carrier systems to transport drugs into renal tubules. The active renal secretion systems include the organic anion transporter (OAT) for weak acids and the organic cation transporter (OCT) for weak bases. Structurally similar drugs can compete for the same transporter, potentially leading to drug accumulation and toxicity. However, this principle can be exploited therapeutically. One example is probenecid (Probalan),...